Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Rilpivirine (RPV)

Atorvastatin

Quality of Evidence: Low

Summary:

Coadministration of rilpivirine (150 mg once daily) and atorvastatin (40 mg once daily) decreased rilpivirine Cmax, AUC and Cmin by 9%, 10% and 10%, respectively. Atorvastatin Cmax and AUC increased by 35% and 4%; Cmin decreased by 15%. Cmax, AUC and Cmin of 2-hydroxy atorvastatin increased by 58%, 39% and 32%, whilst Cmax and AUC of 4-hydroxy atorvastatin increased by 28% and 23%. No dose adjustment is needed for either drug. [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug. The dosing recommendation is applicable to the licensed dose of rilpivirine 25 mg once daily.]

Description:

Coadministration of atorvastatin (40 mg once daily) and a higher than the recommended dose of rilpivirine had no effect on atorvastatin AUC, but decreased Cmin by 15% and increased Cmax by 35%. Rilpivirine AUC and Cmin were unchanged, but Cmax decreased by 9%. No dose adjustment is required.

Edurant Summary of Product Characteristics, Janssen-Cilag Ltd, January 2019.

Coadministration of rilpivirine (150 mg once daily) and atorvastatin (40 mg once daily) was studied in 16 subjects. Rilpivirine Cmax, AUC and Cmin decreased by 9%, 10% and 10%, respectively. Atorvastatin Cmax and AUC increased by 35% and 4%, respectively; Cmin decreased by 15%. Cmax, AUC and Cmin of 2-hydroxy atorvastatin increased by 58%, 39% and 32% , respectively, whilst Cmax and AUC of 4-hydroxy atorvastatin increased by 28% and 23%, respectively. No dose adjustment is needed for either drug.

Edurant US Prescribing Information, Janssen Therapeutics, May 2019.

Coadministration of rilpivirine (150 mg once daily) and atorvastatin (40 mg once daily) was studied in 16 HIV-negative subjects. Rilpivirine Cmax, AUC and Cmin decreased by 9%, 10% and 10%, respectively. Atorvastatin Cmax and AUC increased by 35% and 4%, respectively; Cmin decreased by 15%. Cmax, AUC and Cmin of 2-hydroxy atorvastatin increased by 58%, 39% and 32% , respectively, whilst Cmax and AUC of 4-hydroxy atorvastatin increased by 28% and 23%, respectively.
van Heeswijk RPG, et al. The pharmacokinetic interaction between atorvastatin and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor, in HIV-negative volunteers. 11th European AIDS Conference, Madrid, October 2007, abstract P4.3/04.

View all available interactions with Rilpivirine (RPV) by clicking here.